

Eva Muehlhofer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10091503/publications.pdf>

Version: 2024-02-01

8
papers

703
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

742
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	1.8	18
2	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1193-1205.	3.8	3
3	Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	8
4	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. <i>Circulation</i> , 2022, 145, 1875-1877.	1.6	1
5	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 317-326.	2.8	30
6	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2021, 144, 1831-1841.	1.6	19
7	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. <i>Circulation</i> , 2020, 142, 2219-2230.	1.6	58
8	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020, 382, 1994-2004.	27.0	566